ストックスクリーナーアプリを入手
38.58
0.81%
0.31
前日終値:
$38.27
開ける：
$38.7
24時間の取引高:
154.40K
Relative Volume:
0.07
時価総額：
$7.19B
収益：
$29.52M
当期純損益:
$-567.06M
株価収益率:
-10.54
EPS:
-3.66
ネットキャッシュフロー:
$-551.11M
1週間 パフォーマンス:
+0.47%
1か月 パフォーマンス:
-3.65%
6か月 パフォーマンス:
-6.22%
1年 パフォーマンス:
-17.51%
1日の値動き範囲:
$37.86
$38.78
1週間の範囲:
$37.86
$39.62
52週間の値動き範囲:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
415-766-3638
住所
700 SAGINAW DR, REDWOOD CITY, CA
RVMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
38.58 | 7.04B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.79 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.83 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.56 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.97 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.12 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-15 | 開始されました | Goldman | Buy |
| 2024-07-16 | 繰り返されました | Needham | Buy |
| 2024-07-12 | 開始されました | Barclays | Overweight |
| 2024-07-08 | 開始されました | Jefferies | Buy |
| 2024-04-12 | 繰り返されました | Needham | Buy |
| 2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-04 | 開始されました | Wedbush | Outperform |
| 2023-11-16 | 開始されました | Raymond James | Outperform |
| 2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-10-21 | 開始されました | Oppenheimer | Outperform |
| 2022-05-20 | 開始されました | BofA Securities | Neutral |
| 2022-03-01 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
| 2021-05-18 | 開始されました | Goldman | Buy |
| 2020-05-21 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-09 | 開始されました | Cowen | Outperform |
| 2020-03-09 | 開始されました | Guggenheim | Buy |
| 2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - Seeking Alpha
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - The Manila Times
FDA grants breakthrough therapy designation to Revolution Medicines’ lung cancer drug - Investing.com Canada
How will RVMD's EPS trend in Q1 2025? - AInvest
What analysts say about Revolution Medicines Inc. stockFree Bull & Bear Market Updates - jammulinksnews.com
Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastOutperformance with explosive growth - jammulinksnews.com
What drives Revolution Medicines Inc. stock priceConsistently high returns - jammulinksnews.com
What drives Revolution Medicines Inc. Equity Warrant stock pricePhenomenal trading returns - jammulinksnews.com
Is Revolution Medicines Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Revolution Medicines Inc. Stock Analysis and ForecastRapidly growing investment returns - jammulinksnews.com
What analysts say about Revolution Medicines Inc. Equity Warrant stockExceptional risk-adjusted gains - Autocar Professional
Is Revolution Medicines Inc. Equity Warrant a good long term investmentSky-high profits - Autocar Professional
(RVMD) On The My Stocks Page - news.stocktradersdaily.com
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
What makes Revolution Medicines Inc. Equity Warrant stock price move sharplyInvestor Friendly Risk Reward - beatles.ru
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations - MSN
Revolution Meds partners with AI specialist Iambic - The Pharma Letter
Revolution Medicines partners with Iambic for AI-driven drug discovery By Investing.com - Investing.com South Africa
Revolution Medicines, Inc. and Iambic Therapeutics Announce Technology and Research Collaboration Using Iambic's Ai Discovery Tools to Pursue New Drug Candidates - MarketScreener
Revolution Medicines, Iambic Therapeutics Form AI-Powered Drug Discovery Partnership - MarketScreener
Revolution Medicines partners with Iambic for AI-driven drug discovery - Investing.com
Revolution Medicines And Iambic Therapeutics Partner To Develop Novel Drug Candidates Using AI Models In Multi-Year Collaboration; Iambic To Receive Up To $25M Through A Combination Of Upfront And Expected Near-Term Performance-Based Milesto - 富途牛牛
Revolution Medicines and Iambic Therapeutics Announce Collaboration to Explore Novel Drug Candidates Using Advanced AI Models - Quiver Quantitative
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates - The Manila Times
Revolution Medicines and Iambic Announce Technology and - GlobeNewswire
Revolution Medicines Taps Iambic's AI Platform in $25M Deal to Accelerate Cancer Drug Discovery - Stock Titan
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.28%
大文字化:
|
ボリューム (24 時間):